EARLY USE OF VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A REAL-WORLD ANALYSIS OF HEALTHCARE UTILIZATION

被引：0
|
作者：
Patel, Haridarshan
Khalid, Javaria M.
Shah, Surbhi
Shah, Rikisha
Berger, Ariel
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1728
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [21] REAL-WORLD EXPERIENCE OF USING TOFACITINIB IN ULCERATIVE COLITIS IN BIOLOGIC NAIVE AND BIOLOGIC EXPOSED PATIENTS
    Cheesbrough, Jonathan
    Sharma, Naveen
    Nassar, Islam
    Quraishi, Nabil
    [J]. GUT, 2022, 71 : A42 - A42
  • [22] Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naive and biologic exposed patients
    Cheesbrough, J.
    Quraishi, M. N.
    Sharma, N.
    Nassar, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I443 - I444
  • [23] Hospitalisations, Flares, and Corticosteroid Use Outcomes in Biologic-Naive Patients with Ulcerative Colitis and Crohn's Disease Initiating Vedolizumab
    Alam, Naufil
    Raluy-Callado, Mireia
    Donaldson, Robert
    Kaviya, Arpeat
    Khalid, Javaria
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S26 - S27
  • [24] Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study
    Singh, Siddharth
    Andersen, Nynne Nyboe
    Andersson, Mikael
    Loftus, Edward V., Jr.
    Jess, Tine
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (08) : 1218 - +
  • [25] Comparison of long-term outcomes of infliximab and adalimumab in biologic-naive patients with ulcerative colitis
    Durak, M. B.
    Baspinar, B.
    Guven, I. E.
    Kivrakoglu, F.
    Kilic, V.
    Kosar, K.
    Erdogan, C.
    Yuksel, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I547 - I547
  • [26] TREATMENT DISCONTINUATION, FLARES, AND HOSPITALIZATIONS AMONG BIOLOGIC-NAiVE PATIENTS WITH IBD OVER THE FIRST YEAR OF TREATMENT: A "REAL-WORLD" COMPARATIVE EFFECTIVENESS STUDY OF VEDOLIZUMAB VERSUS INFLIXIMAB
    Patel, Haridarshan
    Raluy-Callado, Mireia
    Berger, Ariel
    Curtis, Rebecca
    Khalid, Javaria Mona
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S78 - S79
  • [27] vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease - a meta-analysis
    Yiu, T. H.
    Leong, R.
    Ko, Y.
    Pudipeddi, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 694 - 694
  • [28] Comparison of long-term outcomes of infliximab and adalimumab in biologic-naive patients with ulcerative colitis
    Durak, M. B.
    Baspinar, B.
    Guven, I. E.
    Kivrakoglu, F.
    Kilic, V.
    Kosar, K.
    Erdogan, C.
    Yuksel, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I547 - I547
  • [29] Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
    Feldman, Steven R.
    Pelletier, Corey L.
    Wilson, Kathleen L.
    Mehta, Rina K.
    Brouillette, Matthew A.
    Smith, David
    Bonafede, Machaon M.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (01) : 45 - 54
  • [30] Vedolizumab Decreases Utilization of Healthcare Resources in Biologic-naive Inflammatory Bowel Disease (IBD) Patients
    Kassim, Olufemi
    Micic, Dejan
    Christensen, Britt
    Lissoos, Trevor
    Luo, Michelle
    Null, Kyle D.
    Cohen, Russell
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S334 - S335
12345